AtriCure (ATRC) Earnings Date & Reports

Key Takeaways

• Third-quarter 2026 revenue reached $154.5 million, up 15% year over year and ahead of the roughly $151 million consensus estimate.
• AtriCure returned to profitability, posting net income of $4.1 million versus a net loss of $0.3 million in the prior-year quarter.
• Adjusted earnings per share (EPS) came in at $0.18, a sharp improvement from an adjusted loss of $0.01 a year earlier.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 50.6% to $26.8 million.
• U.S. pain management and open ablation franchises led the way, growing 34.6% and 20.8%, respectively.
• Management raised its full-year 2026 revenue outlook to a range of $606 million to $610 million.
• For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, visit the additional pages linked here.
• To discover data-driven trade ideas across the market, explore Trending AI Robots.

Earnings Context and Why It Matters

AtriCure is a medical-device innovator focused on surgical treatments for atrial fibrillation (Afib, an irregular heartbeat), left atrial appendage (LAA) management, and post-operative pain management. Its third-quarter 2026 report matters because it tests whether the company can sustain double-digit revenue growth while converting that momentum into durable profitability. Coming off two straight quarters of positive results and a return to GAAP (Generally Accepted Accounting Principles) net income, investors were watching for confirmation that pain management and open ablation could offset persistent softness in minimally invasive ablation. The quarter also carried weight as a checkpoint for full-year guidance and for progress on the BoxX-NoAF clinical trial, a key long-term growth catalyst.

Reported Results

AtriCure reported third-quarter 2026 worldwide revenue of $154.5 million, a 15% increase year over year, or 15.1% in constant currency, exceeding consensus estimates near $151 million. U.S. revenue climbed 17.1% to $128 million, while international revenue rose 5.8% to $26.4 million.

Growth was broad-based across the company's core franchises. U.S. pain management revenue surged 34.6% to $28.1 million, supported by cryoSPHERE MAX and cryoXT. U.S. open ablation grew 20.8% to $43 million, led by the EnCompass Clamp, while U.S. appendage management increased 13.5% to $51.6 million on adoption of AtriClip FLEX-Mini and PRO-Mini devices. Minimally invasive ablation remained the notable weak spot, declining 27.5% to $5.4 million as the market continues to shift toward PFA (pulsed field ablation) catheter therapies.

Profitability improved meaningfully. Net income reached $4.1 million, compared with a $0.3 million loss a year ago. GAAP diluted EPS was $0.08 versus a loss of $0.01, while adjusted EPS of $0.18 handily beat analyst expectations that had projected results near breakeven. Gross margin expanded 180 basis points to 77.3%, and adjusted EBITDA climbed 50.6% to $26.8 million. The company ended the quarter with $187 million in cash and investments after generating $19.2 million in cash.

Management raised its full-year 2026 revenue guidance to approximately $606 million to $610 million, implying annual growth of about 13.4% to 14.1%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener aims to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like AtriCure, it offers a structured way to evaluate the broader medical-device landscape and identify comparable setups.

Market Reaction and Investor Sentiment

Heading into the report, sentiment was broadly positive, with AtriCure shares having rallied sharply over the prior three and twelve months. The company delivered a clear beat on both revenue and earnings, powered by accelerating pain management and open ablation growth and expanding margins. Still, early after-hours trading indicated the stock slipped, suggesting that some investors may have focused on the ongoing contraction in minimally invasive ablation, higher research and development spending tied to the BoxX-NoAF trial, or a valuation that had already priced in much of the strength. The raised full-year revenue guidance provided a constructive signal, but tempered near-term reaction underscores how elevated expectations can shape post-earnings moves even on solid results.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will watch several catalysts tied to AtriCure's clinical pipeline and product roadmap. The BoxX-NoAF trial, studying prevention of post-operative Afib in cardiac surgery patients, has enrolled more than 880 patients, and management expects to complete enrollment by the end of 2026, with a first primary-endpoint data readout anticipated in the spring of 2027. That readout could meaningfully influence the long-term growth narrative.

On the product front, AtriCure recently received FDA 510(k) clearance for a 30-millimeter AtriClip FLEX-Mini device and plans to launch it in December, further differentiating its LAA management platform. Progress on cryoXT in pain management and the anticipated late-2027 launch of AtriClip FLEX-Mini V also remain items to track.

At the same time, the sustained decline in minimally invasive ablation and softness in certain international markets remain headwinds worth monitoring. Margin trajectory will also be in focus, given favorable product and geographic mix alongside costs tied to the new manufacturing facility and elevated clinical spending. The raised full-year revenue range of $606 million to $610 million gives investors a concrete benchmark to measure execution against as the year closes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations